<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>494</serviceExecutionTime><Drug id="18425"><DrugName>ambrisentan</DrugName><DrugNamesKey><Name id="43060436">Letairis</Name><Name id="42863499">Volibris</Name><Name id="42752411">ambrisentan</Name></DrugNamesKey><DrugSynonyms><Name><Value>ambrisentan</Value><Types><Type>INN</Type></Types></Name><Name><Value>BSF-208075</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>LU-302146</Value><Types><Type>Analogue</Type><Type>Research Code</Type></Types></Name><Name><Value>BSF-302146</Value><Types><Type>Analogue</Type><Type>Research Code</Type></Types></Name><Name><Value>BSF-420627</Value><Types><Type>Analogue</Type><Type>Research Code</Type></Types></Name><Name><Value>Volibris</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>GSK-1325760A</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>GSK-132576A</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>LU-208075</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Letairis</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>177036-94-1</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="14356">BASF SE</CompanyOriginator><CompaniesPrimary><Company id="16450">Gilead Sciences Inc</Company><Company id="28355">GlaxoSmithKline plc</Company></CompaniesPrimary><CompaniesSecondary><Company id="13601">Abbott Laboratories</Company><Company id="14356">BASF SE</Company><Company id="16956">Gilead Colorado Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="18425" type="Drug"><TargetEntity id="282368" type="siDrug">Ambrisentan</TargetEntity></SourceEntity><SourceEntity id="13601" type="Company"><TargetEntity id="4295903265" type="organizationId">Abbott Laboratories</TargetEntity></SourceEntity><SourceEntity id="14356" type="Company"><TargetEntity id="4295869198" type="organizationId">BASF SE</TargetEntity></SourceEntity><SourceEntity id="16450" type="Company"><TargetEntity id="4295906595" type="organizationId">Gilead Sciences Inc</TargetEntity></SourceEntity><SourceEntity id="16956" type="Company"><TargetEntity id="4295902923" type="organizationId">Gilead Colorado Inc</TargetEntity></SourceEntity><SourceEntity id="28355" type="Company"><TargetEntity id="4295895781" type="organizationId">GlaxoSmithKline PLC</TargetEntity></SourceEntity><SourceEntity id="1105" type="ciIndication"><TargetEntity id="10039710" type="MEDDRA"/><TargetEntity id="732" type="siCondition"/></SourceEntity><SourceEntity id="1867" type="ciIndication"><TargetEntity id="10037400" type="MEDDRA"/><TargetEntity id="D006976" type="MeSH"/><TargetEntity id="-104458654" type="omicsDisease"/><TargetEntity id="243" type="siCondition"/></SourceEntity><SourceEntity id="3510" type="ciIndication"><TargetEntity id="I27.0" type="ICD10"/><TargetEntity id="10064911" type="MEDDRA"/><TargetEntity id="182090" type="ORPHANET"/><TargetEntity id="2543" type="siCondition"/><TargetEntity id="244" type="siCondition"/></SourceEntity><SourceEntity id="3513" type="ciIndication"><TargetEntity id="70591" type="ORPHANET"/><TargetEntity id="2074" type="siCondition"/></SourceEntity><SourceEntity id="3771" type="ciIndication"><TargetEntity id="J84.112" type="ICD10"/><TargetEntity id="10021240" type="MEDDRA"/><TargetEntity id="D054990" type="MeSH"/><TargetEntity id="2032" type="ORPHANET"/><TargetEntity id="-1110748304" type="omicsDisease"/><TargetEntity id="289" type="siCondition"/></SourceEntity><SourceEntity id="55" type="ciIndication"><TargetEntity id="I50" type="ICD10"/><TargetEntity id="10007554" type="MEDDRA"/><TargetEntity id="D006333" type="MeSH"/><TargetEntity id="-1323949873" type="omicsDisease"/><TargetEntity id="237" type="siCondition"/></SourceEntity><SourceEntity id="69" type="ciIndication"><TargetEntity id="10038435" type="MEDDRA"/><TargetEntity id="346" type="siCondition"/></SourceEntity><SourceEntity id="770" type="Action"><TargetEntity id="141" type="Mechanism">Endothelin ETA Receptor Antagonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00659" type="ciTarget"><TargetEntity id="44256191019093" type="siTarget">Endothelin-1 receptor</TargetEntity><TargetEntity id="-1979653943" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Pulmonary artery hypertension - US - Jun-2007</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="3510">Pulmonary artery hypertension</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1105">Scleroderma</Indication><Indication id="1867">Pulmonary hypertension</Indication><Indication id="3512">Lung disease pulmonary hypertension</Indication><Indication id="3513">Chronic thromboembolic pulmonary hypertension</Indication><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><Indication id="55">Cardiac failure</Indication><Indication id="69">Renal failure</Indication></IndicationsSecondary><ActionsPrimary><Action id="770">Endothelin ET-A receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="7293">Synergist</Action><Action id="388">Vasodilator</Action><Action id="2657">Antihypertensive</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="751">Film coating</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="805">Daily dosing</Technology></Technologies><EphmraCodes><Ephmra><Code>C2</Code><Name>ANTIHYPERTENSIVES</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-26T08:12:10.000Z</LastModificationDate><ChangeDateLast>2019-06-27T00:00:00.000Z</ChangeDateLast><AddedDate>1998-07-28T11:36:47.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Developed and launched by &lt;ulink linkID="16450" linkType="Company"&gt;Gilead Sciences&lt;/ulink&gt; (following  its acquisition of  &lt;ulink linkID="16956" linkType="Company"&gt;Myogen&lt;/ulink&gt;), and comarketed with &lt;ulink linkID="28355" linkType="Company"&gt;GlaxoSmithKline&lt;/ulink&gt; (GSK), ambrisentan (Letairis; Volibris;  GSK-1325760A; GSK-132576A) is an oral endothelin ET-A antagonist. The product is indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening [&lt;ulink linkID="1620692" linkType="Reference"&gt;1620692&lt;/ulink&gt;], [&lt;ulink linkID="1648412" linkType="Reference"&gt;1648412&lt;/ulink&gt;]. In the US, the drug is additionally indicated in combination with &lt;ulink linkID="4119" linkType="Drug"&gt;tadalafil&lt;/ulink&gt; to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability [&lt;ulink linkID="1620692" linkType="Reference"&gt;1620692&lt;/ulink&gt;]. In the EU, it is indicated for the treatment of adults with PAH classified as WHO functional class II and III, including use in combination with tadalafil [&lt;ulink linkID="1706437" linkType="Reference"&gt;1706437&lt;/ulink&gt;], [&lt;ulink linkID="1716113" linkType="Reference"&gt;1716113&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Ambrisentan was launched in the US for PAH in June 2007 [&lt;ulink linkID="805359" linkType="Reference"&gt;805359&lt;/ulink&gt;].  &lt;ulink linkID="28355" linkType="Company"&gt;&lt;/ulink&gt;In April 2008, the EMA approved ambrisentan for the treatment of  functional class II and III PAH [&lt;ulink linkID="900080" linkType="Reference"&gt;900080&lt;/ulink&gt;]; the drug was  launched by GSK in the UK in May 2008 and in Germany in June 2008 [&lt;ulink linkID="1716965" linkType="Reference"&gt;1716965&lt;/ulink&gt;], [&lt;ulink linkID="1338151" linkType="Reference"&gt;1338151&lt;/ulink&gt;]; in November 2015, additional EU approval was granted for use of ambrisentan in combination with &lt;ulink linkID="4119" linkType="Drug"&gt;tadalafil&lt;/ulink&gt;  [&lt;ulink linkID="1716113" linkType="Reference"&gt;1716113&lt;/ulink&gt;]. In October 2015, the FDA approved the use of ambrisentan in combination with tadalinafil in first-line treatment, based on the AMBITION trial [&lt;ulink linkID="1700049" linkType="Reference"&gt;1700049&lt;/ulink&gt;]. In September 2010, GSK launched the drug in Japan for PAH [&lt;ulink linkID="1133535" linkType="Reference"&gt;1133535&lt;/ulink&gt;]. A global phase II trial in pediatric pulmonary   hypertension  began in January 2011 [&lt;ulink linkID="2020808" linkType="Reference"&gt;2020808&lt;/ulink&gt;]; the open-label extension of this trial was ongoing in April 2018 [&lt;ulink linkID="2020814" linkType="Reference"&gt;2020814&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The drug was also previously being developed in a broader pulmonary hypertension patient population.  In August 2006, a phase III trial was initiated patients with pulmonary hypertension deriving from COPD, interstitial lung disease, chronic thromboembolic disease, sickle cell disease, congenital heart defects and HIV (WHO Groups 1 and 3) [&lt;ulink linkID="689058" linkType="Reference"&gt;689058&lt;/ulink&gt;]; positive data were reported in 2009 [&lt;ulink linkID="1010893" linkType="Reference"&gt;1010893&lt;/ulink&gt;]; however no further development has been reported for these indications. In September 2012, the drug was in phase III trials in Japan and overseas for chronic thromboembolic pulmonary hypertension (CTEPH; WHO Group 4) [&lt;ulink linkID="1324911" linkType="Reference"&gt;1324911&lt;/ulink&gt;]; these studies were ongoing in February 2015 [&lt;ulink linkID="1641818" linkType="Reference"&gt;1641818&lt;/ulink&gt;]; however, in April 2015, this indication was no longer under development in Japan [&lt;ulink linkID="1648412" linkType="Reference"&gt;1648412&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Development was also undertaken in other indications. In December 2008, Gilead began a phase III trial for idiopathic pulmonary fibrosis (IPF) [&lt;ulink linkID="979561" linkType="Reference"&gt;979561&lt;/ulink&gt;]. In December 2010, the trial was discontinued after interim analysis revealed lack of efficacy [&lt;ulink linkID="1157638" linkType="Reference"&gt;1157638&lt;/ulink&gt;]. Myogen had also been investigating the drug  for the treatment of chronic renal failure and chronic heart failure [&lt;ulink linkID="431411" linkType="Reference"&gt;431411&lt;/ulink&gt;], however no further development has been reported for these indications. The drug had also been developed for diffuse systemic sclerosis (scleroderma). In March 2010, a clinical study was initiated, which completed in July 2016 [&lt;ulink linkID="1649692" linkType="Reference"&gt;1649692&lt;/ulink&gt;]; no further development was reported. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;&lt;ulink linkID="IN2542249" linkType="Patent"&gt;US-05932730&lt;/ulink&gt; claimed ambrisentan generically, while &lt;ulink linkID="PA3038959" linkType="Patent"&gt;US-07109205&lt;/ulink&gt; specifically claimed the drug. Both are part of the same patent family, based on &lt;ulink linkID="IN2195920" linkType="Patent"&gt;WO-9611914&lt;/ulink&gt;, and would  have expired on October 7, 2015; however, '205 received an extension for patent office delays, meaning it expired on June 21, 2016 [&lt;ulink linkID="767198" linkType="Reference"&gt;767198&lt;/ulink&gt;]. A fourth constraining product patent (RE42462) expired in July 2018 [&lt;ulink linkID="2125642" linkType="Reference"&gt;2125642&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2019, &lt;ulink linkID="20348" linkType="Company"&gt;Teva&lt;/ulink&gt; launched its generic version of ambrisentan tablets (5 and 10 mg) in the US [&lt;ulink linkID="2147474" linkType="Reference"&gt;2147474&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2019, &lt;ulink linkID="15503" linkType="Company"&gt;Cipla&lt;/ulink&gt; received final US FDA approval for its generic version of ambrisentan tablets (5 and 10 mg); at that time, the drug was  immediately launched [&lt;ulink linkID="2147003" linkType="Reference"&gt;2147003&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2019, &lt;ulink linkID="29062" linkType="Company"&gt;Zydus Cadila&lt;/ulink&gt;  received  final approval of an ANDA from the US FDA to market its generic ambrisentan tablets (5 and 10 mg) [&lt;ulink linkID="2136264" linkType="Reference"&gt;2136264&lt;/ulink&gt;], [&lt;ulink linkID="2137078" linkType="Reference"&gt;2137078&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2019, &lt;ulink linkID="28038" linkType="Company"&gt;Mylan Pharmaceuticals&lt;/ulink&gt; received  final approval of an ANDA from the US FDA to market its generic ambrisentan tablets (5 and 10 mg) [&lt;ulink linkID="2137078" linkType="Reference"&gt;2137078&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2019, &lt;ulink linkID="1161942" linkType="Company"&gt;Sun Pharma Global&lt;/ulink&gt; received  final approval of an ANDA from the US FDA to market its generic ambrisentan tablets (5 and 10 mg) [&lt;ulink linkID="2137078" linkType="Reference"&gt;2137078&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, &lt;ulink linkID="29639" linkType="Company"&gt;SigmaPharm Laboratories&lt;/ulink&gt; submitted an ANDA to the FDA requesting permission to manufacture and market a generic version of ambrisentan and alleging that one of the patents associated with ambrisentan tablets was invalid, unenforceable and/or would not be infringed. At that time, Gilead filed a lawsuit against the company [&lt;ulink linkID="1738236" linkType="Reference"&gt;1738236&lt;/ulink&gt;]. In February 2017, a trial date had yet to be set and was expected to occur in 2Q17 [&lt;ulink linkID="1903912" linkType="Reference"&gt;1903912&lt;/ulink&gt;]. The case was consolidated with the Watson case, and dismissed in May 2017 following dismissal of the Watson case [&lt;ulink linkID="1948542" linkType="Reference"&gt;1948542&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2015,  &lt;ulink linkID="1088700" linkType="Company"&gt;Actavis&lt;/ulink&gt; (formerly &lt;ulink linkID="26171" linkType="Company"&gt;Watson&lt;/ulink&gt;) filed an ANDA for the approval of its generic ambrisentan tablets (5 and 10 mg) in the US alleging that one of the patents associated with ambrisentan tablets was invalid, unenforceable and/or would not be infringed; Actavis believed it may be the first to file an ANDA with Paragraph IV certifications and may therefore be entitled to 180 days of market exclusivity. In April 2015, Gilead filed a US lawsuit alleging infringement of the &lt;ulink linkID="IN2542249" linkType="Patent"&gt;US-RE042462&lt;/ulink&gt; patent  [&lt;ulink linkID="1647684" linkType="Reference"&gt;1647684&lt;/ulink&gt;], [&lt;ulink linkID="1641816" linkType="Reference"&gt;1641816&lt;/ulink&gt;]. In January 2017, Gilead reached an agreement with the company to settle the litigation; terms were not disclosed [&lt;ulink linkID="1903912" linkType="Reference"&gt;1903912&lt;/ulink&gt;]. In March 2019, Watson Laboratories received  final approval of an ANDA from the US FDA to market its generic ambrisentan tablets (5 and 10 mg) [&lt;ulink linkID="2137078" linkType="Reference"&gt;2137078&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;SPCs have been granted on &lt;ulink linkID="IN2599387" linkType="Patent"&gt;EP-00785926&lt;/ulink&gt; in most countries in Europe and expire in October 2020. &lt;/para&gt;&lt;para&gt;By May 2019, &lt;ulink linkID="1007988" linkType="Company"&gt;Zentiva&lt;/ulink&gt; had submitted an application for a generic version of the drug; however, by that time, the decision was taken to withdraw the application, following a formulated list of questions from the CHMP regarding unresolved issues [&lt;ulink linkID="2157455" linkType="Reference"&gt;2157455&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2019, the EMA's CHMP adopted a positive opinion for &lt;ulink linkID="18439" linkType="Company"&gt;Mylan&lt;/ulink&gt;'s generic version of the drug [&lt;ulink linkID="2146306" linkType="Reference"&gt;2146306&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In June 2019, &lt;ulink linkID="1047483" linkType="Company"&gt;Sino Biopharma&lt;/ulink&gt; filed an ANDA for its generic version of the drug in China [&lt;ulink linkID="2158241" linkType="Reference"&gt;2158241&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In April 2019, &lt;ulink linkID="1025425" linkType="Company"&gt;Chiatai Tianqing Pharmaceutical&lt;/ulink&gt; received an ANDA approval  for its generic version of ambrisentan in China [&lt;ulink linkID="2150657" linkType="Reference"&gt;2150657&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2017, &lt;ulink linkID="1017684" linkType="Company"&gt;Jiangsu Hansoh Pharmaceutical Group&lt;/ulink&gt; submitted a filing for its generic version of ambrisentan; in September 2017, the application was granted Priority Review in China [&lt;ulink linkID="1958244" linkType="Reference"&gt;1958244&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In August 2004, the FDA granted Orphan Drug status for PAH [&lt;ulink linkID="552210" linkType="Reference"&gt;552210&lt;/ulink&gt;]. In March 2006, the agency also granted Fast Track status [&lt;ulink linkID="654806" linkType="Reference"&gt;654806&lt;/ulink&gt;]. In December 2009, the FDA awarded Orphan status for IPF [&lt;ulink linkID="1276550" linkType="Reference"&gt;1276550&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2006, Gilead submitted a NDA to the FDA for ambrisentan as a  treatment of PAH  [&lt;ulink linkID="752283" linkType="Reference"&gt;752283&lt;/ulink&gt;]. In February 2007, the FDA accepted the NDA for review and granted it Priority Review status [&lt;ulink linkID="766867" linkType="Reference"&gt;766867&lt;/ulink&gt;]. In June 2007, the FDA approved the drug for PAH   in patients with WHO Functional Class II or III symptoms to improve exercise capacity and delay clinical worsening, and the drug was launched immediately [&lt;ulink linkID="805359" linkType="Reference"&gt;805359&lt;/ulink&gt;], [&lt;ulink linkID="805398" linkType="Reference"&gt;805398&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In December 2014, an sNDA was filed to extend the label of the drug  for ambrisentan in combination with &lt;ulink linkID="4119" linkType="Drug"&gt;tadalafil&lt;/ulink&gt; based on the AMBITION study for the initial treatment of PAH [&lt;ulink linkID="1640009" linkType="Reference"&gt;1640009&lt;/ulink&gt;], [&lt;ulink linkID="1689538" linkType="Reference"&gt;1689538&lt;/ulink&gt;]; in August 2015, it was reported that the FDA granted a standard review  [&lt;ulink linkID="1689538" linkType="Reference"&gt;1689538&lt;/ulink&gt;]. In October 2015, the FDA approved the use of ambrisentan in combination with tadalafil for PAH in first-line PAH patients  [&lt;ulink linkID="1700049" linkType="Reference"&gt;1700049&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;By May 2005, Orphan Drug status had  been granted in the EU for PAH and CTPH [&lt;ulink linkID="598614" linkType="Reference"&gt;598614&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2007, the EMA validated GSK's MAA for the drug and distributed it for formal review by the CHMP [&lt;ulink linkID="777450" linkType="Reference"&gt;777450&lt;/ulink&gt;]; GSK received a positive opinion from the CHMP in February 2008 [&lt;ulink linkID="878954" linkType="Reference"&gt;878954&lt;/ulink&gt;]. In April 2008, ambrisentan was approved for the treatment of functional class II and III PAH, and the first European launches were planned for summer 2008 [&lt;ulink linkID="900080" linkType="Reference"&gt;900080&lt;/ulink&gt;]. The drug was launched by GSK in Germany in  June 2008 [&lt;ulink linkID="1338151" linkType="Reference"&gt;1338151&lt;/ulink&gt;]. In August  2008, the drug was launched in Denmark [&lt;ulink linkID="1423684" linkType="Reference"&gt;1423684&lt;/ulink&gt;].  In November 2008, the drug was launched in Sweden [&lt;ulink linkID="1412456" linkType="Reference"&gt;1412456&lt;/ulink&gt;].    In January 2009, the drug was launched in France [&lt;ulink linkID="1348853" linkType="Reference"&gt;1348853&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2009, the drug was launched in Switzerland by GSK, for PAH [&lt;ulink linkID="1616181" linkType="Reference"&gt;1616181&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2014, ambrisentan in combination with tadalafil was filed for EU approval for the initial treatment of PAH [&lt;ulink linkID="1620464" linkType="Reference"&gt;1620464&lt;/ulink&gt;]; in October 2015, the EMA's CHMP issued a positive opinion for the approval of ambrisentan in the EU for use in combination treatment for patients with PAH [&lt;ulink linkID="1706152" linkType="Reference"&gt;1706152&lt;/ulink&gt;], [&lt;ulink linkID="1706157" linkType="Reference"&gt;1706157&lt;/ulink&gt;]; in November 2015, approval was granted in the EU for the extended use of  ambrisentan as combination treatment based on data from the AMBITION study [&lt;ulink linkID="1716113" linkType="Reference"&gt;1716113&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In May 2007, ambrisentan was granted Orphan Drug designation in Japan for PAH [&lt;ulink linkID="1133535" linkType="Reference"&gt;1133535&lt;/ulink&gt;], [&lt;ulink linkID="1441861" linkType="Reference"&gt;1441861&lt;/ulink&gt;]. In July 2010, the drug was approved in Japan for PAH [&lt;ulink linkID="1128603" linkType="Reference"&gt;1128603&lt;/ulink&gt;]; and in September 2010, ambrisentan was launched [&lt;ulink linkID="1133535" linkType="Reference"&gt;1133535&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2013, ambrisentan was granted Orphan Drug designation in Japan for CTPH [&lt;ulink linkID="1441861" linkType="Reference"&gt;1441861&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In October 2010, it was approved  by the SFDA [&lt;ulink linkID="1259130" linkType="Reference"&gt;1259130&lt;/ulink&gt;]; by February 2012, it had been launched   for the treatment of  functional class II and III PAH [&lt;ulink linkID="1259131" linkType="Reference"&gt;1259131&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;By June 2015, ambrisentan had been approved, and presumably launched, in Canada for the treatment of PAH [&lt;ulink linkID="1687643" linkType="Reference"&gt;1687643&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt;By April 2009, the product had been approved, and presumably launched, in Israel for PAH [&lt;ulink linkID="1687648" linkType="Reference"&gt;1687648&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;In December 2008, the South Korean FDA designated the agent as an Orphan drug for PAH [&lt;ulink linkID="975024" linkType="Reference"&gt;975024&lt;/ulink&gt;]. In April 2009, the drug (as Volibris) was approved in Korea [&lt;ulink linkID="1747964" linkType="Reference"&gt;1747964&lt;/ulink&gt;]. In November 2011, the agent was launched [&lt;ulink linkID="1942200" linkType="Reference"&gt;1942200&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2009, ambrisentan was granted Orphan Drug status for PAH [&lt;ulink linkID="1685979" linkType="Reference"&gt;1685979&lt;/ulink&gt;], [&lt;ulink linkID="1941145" linkType="Reference"&gt;1941145&lt;/ulink&gt;]. In August 2012, the drug was approved in Taiwan for PAH [&lt;ulink linkID="1685979" linkType="Reference"&gt;1685979&lt;/ulink&gt;]; by February 2014, the product was launched there as Volibris [&lt;ulink linkID="1685980" linkType="Reference"&gt;1685980&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2014, the drug had been granted Orphan Drug status for the treatment of PAH in Australia [&lt;ulink linkID="1620464" linkType="Reference"&gt;1620464&lt;/ulink&gt;]. By June 2015, ambrisentan had been approved, and presumably launched, in Australia and New Zealand for PAH [&lt;ulink linkID="1687639" linkType="Reference"&gt;1687639&lt;/ulink&gt;], [&lt;ulink linkID="1687641" linkType="Reference"&gt;1687641&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;In March 2011, the FDA approved the removal of the potential risk of liver injury from the boxed warning of the prescribing information. A boxed warning regarding  the risk of serious birth defects and the contraindication for use during pregnancy remained [&lt;ulink linkID="1173241" linkType="Reference"&gt;1173241&lt;/ulink&gt;], [&lt;ulink linkID="1173347" linkType="Reference"&gt;1173347&lt;/ulink&gt;]; by June 2015, the boxed warning had been updated regarding the potential risk of birth defects and ambrisentan was only available to  female patients through a restricted program called the Letairis Risk Evaluation and Mitigation Strategy [&lt;ulink linkID="805359" linkType="Reference"&gt;805359&lt;/ulink&gt;]. In July 2012, GSK and Health Canada reported that the drug was associated with higher disease progression and death rates in the discontinued IPF trial. The product information was updated with a contraindication for use in IPF patients [&lt;ulink linkID="1308146" linkType="Reference"&gt;1308146&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;&lt;subtitle&gt;Pulmonary arterial hypertension&lt;/subtitle&gt;In November 2009, a phase IIIb/IV, randomized, double-blind, multicenter study of first-line combination therapy with ambrisentan and tadalafil in subjects with PAH (&lt;ulink linkID="68965" linkType="Protocol"&gt;NCT01178073&lt;/ulink&gt;; AMBITION) was planned. Treatment-naive patients (expected n = 300)  were to be randomized to receive either the combination of ambrisentan (10 mg) and  tadalafil (40 mg), or ambrisentan/tadalafil monotherapy, with a primary endpoint of time to clinical failure.  Enrollment began in October 2010, and the trial was completed in August 2014 [&lt;ulink linkID="1053724" linkType="Reference"&gt;1053724&lt;/ulink&gt;], [&lt;ulink linkID="1207265" linkType="Reference"&gt;1207265&lt;/ulink&gt;]. In October 2014, GSK stated that positive data had been obtained from the trial [&lt;ulink linkID="1604329" linkType="Reference"&gt;1604329&lt;/ulink&gt;].  In October 2014, clinical data were presented at Chest 2014 in Austin, TX. When compared pooled with combination monotherapy, time to clinical failure hazard ratio was estimated to be 0.505 and 0.506 for the patients from North America and rest of the world, respectively; 0.524 and 0.454 for patients with &amp;lt; 65 and &amp;gt;/= 65 years of age; 0.473 and 0.581 for females and males, respectively [&lt;ulink linkID="1620434" linkType="Reference"&gt;1620434&lt;/ulink&gt;]. In February 2015, similar data were reported showing that the combination  of ambrisentan plus tadalafil  reduced the   risk of clinical failure by 50% compared with pooled data from both monotherapy arms. The primary endpoint of time to clinical failure was also significant  for the combination therapy when compared with the individual monotherapy groups [&lt;ulink linkID="1641816" linkType="Reference"&gt;1641816&lt;/ulink&gt;]. In May 2015, further clinical data were presented at the 2015 ATS International Conference in Denver, CO. Overall, PAH related hospitalizations were noted in 8 and 18% of patients in combination and monotherapy groups, respectively, with a 63% risk reduction was observed in combination therapy when compared with monotherapies [&lt;ulink linkID="1679505" linkType="Reference"&gt;1679505&lt;/ulink&gt;]. In June 2015, further clinical data were presented at the 16th EULAR Annual European Congress in Rome, Italy.​  The combination reduced the risk of delayed time to clinical failure  by 57% when compared with monotherapies, with a reduction in hospitalizations primarily driving the treatment effect. Serious adverse events were noted in 44, 34, and 50% of patients receiving Ambrisentan + tadalafil, ambrisentan and tadalafil, respectively  [&lt;ulink linkID="1667640" linkType="Reference"&gt;1667640&lt;/ulink&gt;]. In August 2015, further primary analysis data from 500 patients were published; the primary endpoint of time to first clinical failure event  occurred in 18, 34 and 28% in the combination-therapy, ambrisentan-monotherapy and tadalafil-monotherapy groups, respectively  [&lt;ulink linkID="1689538" linkType="Reference"&gt;1689538&lt;/ulink&gt;], [&lt;ulink linkID="1689645" linkType="Reference"&gt;1689645&lt;/ulink&gt;]. In September 2015, further clinical data were presented at the 2015 ESC Congress in London, UK. The study demonstrated that both initial combination therapy with ambrisentan and tadalafil and monotherapy with ambrisentan/tadalafil improved hemodynamics and exercise capacity, and the initial combination therapy was associated with statistically significant larger improvements as compared with monotherapy in patients with PAH [&lt;ulink linkID="1693480" linkType="Reference"&gt;1693480&lt;/ulink&gt;]. In October 2015, further data from the 605-patient trial were reported. The ambrisentan/tadalafil combination therapy was superior in reducing the risk of the composite primary endpoint by 49 and 45%, compared with ambrisentan or tadalafil monotherapy, respectively. Overall, 20% of patients receiving the combination experienced a primary endpoint event compared with 35 and 30%, for patients treated with ambrisentan or tadalafil alone, respectively. In patients treated with the combination, a reduced risk of hospitalization for worsening PAH of 67 and 56% was observed compared with ambrisentan or tadalafil, respectively. At week 24, a median difference of 24 and 20 m in 6MWD improvement from baseline with the combination therapy was observed compared with ambrisentan or tadalafil, respectively [&lt;ulink linkID="1700049" linkType="Reference"&gt;1700049&lt;/ulink&gt;].  In September 2015,  further data were presented at the 25th ERS Congress in Amsterdam, the Netherlands. Time to clinical failure, was significantly reduced with the combination versus pooled monotherapy (p &amp;lt; 0.0001) and also versus ambrisentan (p = 0.0002) and tadalafil (p = 0.0023) monotherapy [&lt;ulink linkID="1700130" linkType="Reference"&gt;1700130&lt;/ulink&gt;]. In May 2017, further data of the effect of initial combination therapy of ambrisentan and tadalafil versus monotherapy on health-related quality of life (HRQoL) were presented at the 2017 ATS International Conference in Washington DC. Mean difference between combination and pooled monotherapy in change from baseline to week 24 for components of the Short form (SF)-36 like physical component summary, mental component summary and heat transition was 0.79 (p =0.274), 1.07 (p = 0.284) and -0.32 (p = 0.004), respectively; and for domains of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) like overall symptom score, QoL score and activity  score was -0.72 (p = 0.205), -0.88 (p = 0.082) and -0.65(p = 0.204), respectively. For all components of the SF-36 and all domains of the CAMPHOR, HRQoL score improved compared with baseline in both the combination therapy and pooled monotherapy groups [&lt;ulink linkID="1929690" linkType="Reference"&gt;1929690&lt;/ulink&gt;]. In September 2018, further clinical data were presented at the 28th ERS International Congress in Paris, France. Through week-16, &amp;gt;/= 0, &amp;gt;/= 30, &amp;gt;/= 60, &amp;gt;/= 90 and &amp;gt;/= 120 meter improvement from baseline  in 6 meter walk distance was reported in 69.3, 42.2, 25, 13.1 and 6.1% (pooled monotherapy), 60.2, 57.7, 31.5, 17.3 and 8.9% (combination therapy), respectively, whereas &amp;gt;/= 0, &amp;gt;/= 300, &amp;gt;/= 600, &amp;gt;/= 900 and &amp;gt;/= 1200 ng/ml improvement in NT-pro-BNP was observed in 78.7, 48.8, 33, 23.7 and 17.2% (pooled monotherapy), 82.7, 59.1, 50.5, 40.3 and 32.7% (combination therapy), respectively [&lt;ulink linkID="2072846" linkType="Reference"&gt;2072846&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2008, an observational phase IV trial (&lt;ulink linkID="16666" linkType="Protocol"&gt;NCT00679224&lt;/ulink&gt;; VOLT) was planned in patients (expected n = 800) prescribed ambrisentan in several European countries. The study started in June 2008, and was expected to complete in November 2012 [&lt;ulink linkID="913845" linkType="Reference"&gt;913845&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2008, a randomized, double-blind phase IV trial (&lt;ulink linkID="15448" linkType="Protocol"&gt;NCT00617305&lt;/ulink&gt;; ATHENA-1) was initiated in patients with PAH failing &lt;ulink linkID="8713" linkType="Drug"&gt;sildenafil&lt;/ulink&gt; monotherapy in the US. Patients were randomized to receive 20 mg oral sildenafil in combination with 5 or 10 mg/day oral ambrisentan or placebo for 24 weeks. The primary endpoint was change from baseline in pulmonary vascular resistance at week 24. The study was expected to complete in July 2011.  [&lt;ulink linkID="902194" linkType="Reference"&gt;902194&lt;/ulink&gt;], [&lt;ulink linkID="901843" linkType="Reference"&gt;901843&lt;/ulink&gt;].&lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Pulmonary arterial hypertension&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In January 2011, a global phase II trial (&lt;ulink linkID="76311" linkType="Protocol"&gt;NCT01332331&lt;/ulink&gt;) began in pediatric patients with pulmonary hypertension to evaluate a low and a high dose in patients aged aged 8 to 18 years (24 weeks). The trial was to enroll 66 patients and complete in May 2018 [&lt;ulink linkID="2020808" linkType="Reference"&gt;2020808&lt;/ulink&gt;]. An open-label extension to this trial (&lt;ulink linkID="76897" linkType="Protocol"&gt;NCT01342952&lt;/ulink&gt;) began in June 2011 and was to complete in October 2022 [&lt;ulink linkID="2020814" linkType="Reference"&gt;2020814&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2007, an open-label, single group phase II/III trial study (&lt;ulink linkID="5312" linkType="Protocol"&gt;NCT00540436&lt;/ulink&gt;, AMB107816) was initiated in patients (expected n = 25) with PAH in Japan.  The primary endpoint was exercise capacity measured through a 6-min walking distance at 4-week intervals for 24 weeks [&lt;ulink linkID="846814" linkType="Reference"&gt;846814&lt;/ulink&gt;]. The study completed in December 2008. An improvement in 6MWD was observed as early as week 4 and continued up to week 16. The mean change from baseline was 33.49 m at week 12, and increased to 46.82 m at week 24. Improvements in BDI, change in WHO Functional Class, cardiopulmonary hemodynamics, and BNP were observed at week 12 and maintained or further improved at week 24. Common adverse events were headache, nasal congestion, hot flush, flushing, peripheral edema, rash, hypotension, dizziness, epistaxis and anaemia. There were two deaths, both considered unrelated to ambrisentan [&lt;ulink linkID="1207237" linkType="Reference"&gt;1207237&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In August 2006, the long-term, open-label, multicenter ARIES-3 study was initiated in North America. The phase III (&lt;ulink linkID="5964" linkType="Protocol"&gt;NCT00380068&lt;/ulink&gt;, AMB-323) study was to enroll patients with various forms of PAH, including PAH associated with interstitial lung disease (WHO Group 3), chronic thromboembolic disease, sickle cell disease, COPD, congenital heart defects and HIV. The trial would also recruit patients receiving prostacyclin or &lt;ulink linkID="8713" linkType="Drug"&gt;sildenafil&lt;/ulink&gt; and those who had discontinued &lt;ulink linkID="5871" linkType="Drug"&gt;bosentan&lt;/ulink&gt; or &lt;ulink linkID="12141" linkType="Drug"&gt;sitaxsentan&lt;/ulink&gt;. Patients with left heart disease or left heart failure were excluded. The primary endpoint was the change in 6-min walk distance (6MWD) from baseline after 24 weeks. Secondary endpoints included clinical worsening of PH, change from baseline in WHO functional class and the Borg dyspnea index [&lt;ulink linkID="689058" linkType="Reference"&gt;689058&lt;/ulink&gt;], [&lt;ulink linkID="856331" linkType="Reference"&gt;856331&lt;/ulink&gt;]. In May 2009, results from the 224-patient study were presented at the International Conference of the American Thoracic Society in San Diego, CA. Patients received ambrisentan 5 mg qd for 24 weeks. Data showed that in the overall study population, patients experienced a mean 21-m improvement in 6MWD at week 24 (95% CI: 11.8 to 29.3); at the same evaluation point, 97% of patients were still alive and Kaplan-Meier analysis of the probability of no clinical worsening across all patients was 90%. Adverse events reported included mild-to-moderate peripheral edema, headache, dyspnea, upper respiratory tract infection, nasal congestion, fatigue and nausea [&lt;ulink linkID="1010893" linkType="Reference"&gt;1010893&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;In December 2003, Myogen was planning two pivotal phase III trials (ARIES I and II; &lt;ulink linkID="49024" linkType="Protocol"&gt;NCT00091598&lt;/ulink&gt;). The trials were to be randomized, double-blind, placebo-controlled studies of ambrisentan in patients with PAH. The company planned to enroll 186 patients (62 patients per dose group) in each trial. ARIES-I would evaluate ambrisentan 5 and 10 mg/day po for 12 weeks to patients in the US and Canada. ARIES-II would evaluate doses of 2.5 and 5 mg/day for 12 weeks in Europe and South America. The primary efficacy endpoint was an increase in exercise capacity [&lt;ulink linkID="516093" linkType="Reference"&gt;516093&lt;/ulink&gt;]. In January 2004, ARIES-I (in North America and Australia) and ARIES-II (in Western and Eastern Europe, Israel and South America) were initiated [&lt;ulink linkID="518605" linkType="Reference"&gt;518605&lt;/ulink&gt;],  [&lt;ulink linkID="582980" linkType="Reference"&gt;582980&lt;/ulink&gt;]. By February 2005,  ARIES-I enrollment was slower than expected due to a decline in the availability of treatment-naive PAH patients [&lt;ulink linkID="582980" linkType="Reference"&gt;582980&lt;/ulink&gt;]. In July 2005, enrollment in ARIES-II was completed  [&lt;ulink linkID="613575" linkType="Reference"&gt;613575&lt;/ulink&gt;], and the last of the 192 patients had completed the 12-week trial by October 2005 [&lt;ulink linkID="632049" linkType="Reference"&gt;632049&lt;/ulink&gt;]. By November 2005, ARIES-I had fully enrolled all 186 patients [&lt;ulink linkID="633940" linkType="Reference"&gt;633940&lt;/ulink&gt;]. In December 2005, top-line results from ARIES-II were reported. The primary efficacy endpoint of ARIES-II was the placebo-corrected mean change in 6-min walk distance (6MWD) at week 12 compared to baseline. Once-daily 5 mg ambrisentan improved 6MWD by 59.4 m and 2.5 mg ambrisentan improved 6MWD by 32.3 m. Improvements in time-to-clinical worsening compared to placebo were observed for both dose groups. The drug was well tolerated [&lt;ulink linkID="639782" linkType="Reference"&gt;639782&lt;/ulink&gt;]. Results from ARIES-I were reported in April 2006. After 12 weeks, subjects receiving 10 mg/day of ambrisentan had a 51.4 m 6MWD increase, while 6MWD increased by 30.6 m in patients given a 5 mg/day dose. With placebo, mean 6MWD decreased by 7.8 m. Time-to-clinical worsening did not reach statistical significance because of the low rate of clinical worsening events. Ambrisentan was well tolerated and did not interact with &lt;ulink linkID="44375" linkType="Drug"&gt;warfarin&lt;/ulink&gt;-type anticoagulants. The most frequent adverse event was peripheral edema and no ambrisentan patients developed serum aminotransferase levels three-fold higher than normal, compared with two placebo subjects [&lt;ulink linkID="661146" linkType="Reference"&gt;661146&lt;/ulink&gt;]. In May 2006,  results for the integrated analysis of ARIES-I and ARIES-II were reported; ARIES-I enrolled 202 patients and ARIES-II enrolled 192 patients. At that time, approximately 400 patients were continuing treatment in long-term trials with maximum exposure of more than 3 years [&lt;ulink linkID="665501" linkType="Reference"&gt;665501&lt;/ulink&gt;]. Similar data were presented in October 2006, at the CHEST 2006 meeting in Salt Lake City, UT. In addition to improving endurance, patients receiving ambrisentan also showed reduced levels of brain naturetic peptide. After 12 weeks the levels of the peptide had decreased by 62.5 pg/ml in the 5 mg dose group and 149.3 pg/ml in the 10 mg dose group. In the placebo group the levels of peptide had increased by 11.8 pg/ml [&lt;ulink linkID="737264" linkType="Reference"&gt;737264&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2007, data from a long-term extension study were presented at the International Conference of the American Thoracic Society in San Francisco, CA. In PAH patients previously treated in the ARIES I and II trials, improvements in the non-placebo-corrected 6MWD was sustained for at least 48 weeks. Improvements in WHO functional class and Borg dyspnea index were also maintained with long-term  treatment. The one-year probability of survival was 95% for patients receiving ambrisentan. As of October 2006, 2.1% of subjects had developed liver enzyme elevations &amp;gt; 3-fold the upper limit of normal, similar to the incidence observed in placebo groups in ARIES-1 and ARIES-2. One patient required discontinuation of ambrisentan due to liver enzyme abnormalities. The most common adverse event was peripheral edema, which was generally mild-or-moderate and did not lead to discontinuation of treatment [&lt;ulink linkID="797500" linkType="Reference"&gt;797500&lt;/ulink&gt;]. In June 2007, further data were reported from the long-term follow up which showed that, of the 393 patients enrolled in the two trials, 94% were still receiving the drug as a monotherapy and a significant delay in clinical-time-to worsening was seen [&lt;ulink linkID="805359" linkType="Reference"&gt;805359&lt;/ulink&gt;]. In October 2007, similar data were reported  at the  annual American College of Chest Physicians meeting in Chicago, IL [&lt;ulink linkID="843035" linkType="Reference"&gt;843035&lt;/ulink&gt;]. Two-year follow-up data from ARIES-1 and -2 were presented in October 2008. The probability of no clinical worsening at 2 years was 72% [&lt;ulink linkID="957027" linkType="Reference"&gt;957027&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2008, a post-hoc analysis of data from the ARIES-1, ARIES-2 and ARIES-E studies was presented, comparing early treatment of PAH with ambrisentan with delayed treatment. The analysis evaluated one-year clinical outcomes in  patients (PLB/ABS) who received placebo in the original ARIES studies followed by  ambrisentan at week 12 and  onwards in the  long-term, open-label ARIES-E extension study to those (ABS/ABS) who received ambrisentan throughout. At week 48, 6MWD  in the ABS/ABS group was over 47 m compared to 33 m in the PLB/ABS group. At year 1, the probability of no clinical worsening was 84% in the ABS/ABS group compared to 76% in the PLB/ABS group [&lt;ulink linkID="908034" linkType="Reference"&gt;908034&lt;/ulink&gt;], [&lt;ulink linkID="911276" linkType="Reference"&gt;911276&lt;/ulink&gt;]. In   November 2015, further clinical data were presented at the 79th Annual ACR meeting, in San Francisco, CA. Majority of patients were free of clinical worsening events through three years of treatment and the time to clinical worsening were similar between idiopathic PAH and CTD-PAH patients [&lt;ulink linkID="1709819" linkType="Reference"&gt;1709819&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In May 2017, data from an open-label trial (ANGEL; &lt;ulink linkID="71410" linkType="Protocol"&gt;NCT01224210&lt;/ulink&gt;) of ambrisentan in patients with portopulmonary hypertension (PoPH), a subset of PAH, were presented at the 2017 ATS International Conference in Washington, DC. Patients (n = 31) received a 5-mg/day dose of ambrisentan that was increased to 10 mg/day at week 4 if tolerated. The drug was well tolerated by most patients, with seven patients discontinuing the study. Of the 170 AEs reported, 38 (22.3%) were considered drug related, with edema (23.6%) and headache (13.1%) the most-frequently reported drug-related AEs. One drug-related serious AE of anemia was reported in a patient who temporarily discontinued treatment; following reintroduction the drug was well tolerated. The safety profile of ambrisentan in patients with PoPH was found to be similar to that in patients with PAH [&lt;ulink linkID="1929624" linkType="Reference"&gt;1929624&lt;/ulink&gt;], [&lt;ulink linkID="1929387" linkType="Reference"&gt;1929387&lt;/ulink&gt;]. Further efficacy data were presented at the same conference. At week-24, pulmonary vascular resistance and other hemodynamic variables improved significantly; cardiac output was 7.3 l/min (p &amp;lt; 0.001), cardiac index was 3.5 l/min.m2 (p &amp;lt; 0.001), pulmonary vascular resistance was 306.3 WU (p &amp;lt; 0.001), mean pulmonary artery pressure was 38.09 mmHg (p = 0.002), pulmonary capillary wedge pressure was 13.1 mmHg, and mean right atrial pressure was 8.5 mmHg (p = 0.014). At week-24, 6 min walk distance (co-primary endpoint) remained stable without any significant improvements [&lt;ulink linkID="1929653" linkType="Reference"&gt;1929653&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2014, a randomized, double-blind, controlled, parallel group, proof-of-concept phase II  (EDITA) trial (&lt;ulink linkID="215890" linkType="Protocol"&gt;NCT02290613&lt;/ulink&gt;; 2014-05ED) to assess safety and efficacy of ambrisentan was planned to be initiated in patients (expected n=38) with borderline PAH associated with systemic sclerosis (SSc-APAH) in November 2014. At that time, the study was expected to be completed in December 2016 [&lt;ulink linkID="1613982" linkType="Reference"&gt;1613982&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2005, Myogen published results from a phase II trial in 64 patients with idiopathic PAH or PAH associated with collagen vascular disease, anorexigen use, or HIV infection. Patients received one of four doses of the drug once daily for 12 weeks, followed by 12 weeks of open-label ambrisentan. At 12 weeks, ambrisentan increased 6MWD in each dose group. Improvements were also seen in dyspnea index, WHO functional class, mean pulmonary arterial pressure and cardiac index. Adverse events were mild and unrelated to dose [&lt;ulink linkID="617464" linkType="Reference"&gt;617464&lt;/ulink&gt;], [&lt;ulink linkID="617569" linkType="Reference"&gt;617569&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2005, Myogen began a LFT rescue trial (AMB-222) in 30 PAH patients who had discontinued &lt;ulink linkID="5871" linkType="Drug"&gt;bosentan&lt;/ulink&gt;  or sitaxsentan  therapy due to serum aminotransferase abnormalities. The study was to assess aminotransferase concentrations associated with ambrisentan, as well as safety, tolerability and efficacy in this population. Subjects were to receive 2.5 mg of the drug daily for 4 weeks, followed by 5 mg daily. The primary endpoint would be assessed after the first 12 weeks of treatment. Patients who completed a 48-week extended portion of the study would have the option to receive 10 mg of the drug [&lt;ulink linkID="602632" linkType="Reference"&gt;602632&lt;/ulink&gt;]. By November 2005, Myogen had  closed screening in the trial, after exceeding the  target of 30 patients.  A total of 36 patients had enrolled, of whom 31 (86%) had discontinued bosentan, 2 (6%) had discontinued sitaxsentan and 3 (8%) had discontinued both bosentan and sitaxsentan, sequentially, due to serum aminotransferase abnormalities. Also, 17 (47%) were receiving concomitant &lt;ulink linkID="8713" linkType="Drug"&gt;sildenafil&lt;/ulink&gt; therapy.  The final patient enrolled in the study would reach the 12-week endpoint evaluation in January 2006 [&lt;ulink linkID="632049" linkType="Reference"&gt;632049&lt;/ulink&gt;]. In February 2006, top-line results  showed that none of the 36 patients  enrolled had a recurrence of liver abnormalities during the 12-week evaluation period. At week 12, one patient showed a transient aminotranferase test result &amp;gt;3-fold the upper limit of the normal range,  resulting in a dose reduction from 5 to 2.5 mg ambrisentan. After a 9-month follow-up period (mean exposure of 6 months), no further occurrence of serum aminotransferase concentrations increases had been observed [&lt;ulink linkID="649918" linkType="Reference"&gt;649918&lt;/ulink&gt;]. In May 2007, similar data were presented at the International Conference of the American Thoracic Society in San Francisco, CA [&lt;ulink linkID="797500" linkType="Reference"&gt;797500&lt;/ulink&gt;]. In June 2007, further data were reported. During the second portion of the trial, 50% of patients received an increased dose of 10 mg. The most common adverse events were peripheral edema, headache, dyspnea and flushing [&lt;ulink linkID="805359" linkType="Reference"&gt;805359&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2003, a phase II trial (AMB-220) was underway [&lt;ulink linkID="535786" linkType="Reference"&gt;535786&lt;/ulink&gt;]. In May 2004, results AMB-220 demonstrated a significant increase in the primary efficacy endpoint, mean 6-min walk distances, in all dose groups evaluated. The data were presented at the 100th Annual American Thoracic Society conference in Orlando, FL [&lt;ulink linkID="540209" linkType="Reference"&gt;540209&lt;/ulink&gt;]. In May 2005, further data from AMB-220 and its subsequent open-label long-term study, AMB-220-E, were reported at the annual International Conference of the American Thoracic Society. Of the 64 patients enrolled in AMB-220, 23 patients had WHO class II symptoms and 41 had WHO class III symptoms. The mean baseline 6MWD for patients with class II symptoms was 390 m at baseline and in patients with class III symptoms it was 316 m. At 12 weeks, the 6MWD was 37.7 m for patients with class II symptoms and 35.2 m for patients with class III symptoms, while at 24 weeks these values were 58.3 and 51.9 m, respectively. These improvements were accompanied with sustained or improved levels of dyspnea compared to baseline for both classes. Also presented were 1-year data demonstrating that ambrisentan had a significant and durable benefit on clinical measures of PAH including exercise capacity. These data also indicated a survival benefit to patients treated with ambrisentan when compared to predicted survival. Of the original 64 patients enrolled, 54 enrolled in the open-label long-term study. The mean dose for these patients was 7.5 mg once daily, with all patients being maintained on ambrisentan monotherapy. At week 48, mean improvement from baseline in 6MWD was 54.5 m. A significant and durable benefit in Borg dyspnea index after exercise was also observed. A total of 57% of patients experienced an improvement in WHO functional class, while 5% had a worsening of functional status. The one-year survival observed in 39 patients with idiopathic PAH was 92% compared to a predicted survival of 74%. In patients with secondary PAH, one-year survival was 95%.  Adverse events were comparable with those reported for the first 12 weeks of treatment, with the majority of the events occurring in the first 12 weeks [&lt;ulink linkID="603292" linkType="Reference"&gt;603292&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In January 2007, a placebo-controlled, randomized, double-blind, dose-escalating phase I trial (&lt;ulink linkID="29970" linkType="Protocol"&gt;NCT00424034&lt;/ulink&gt;; AMB107623; AMD107623) was planned in healthy subjects (expected n = 32) in Japan. The subjects were to receive single oral doses of the drug and the effect of food on the drug's pharmacokinetics was to be assessed. The primary endpoint was adverse event profile [&lt;ulink linkID="780719" linkType="Reference"&gt;780719&lt;/ulink&gt;]. The trial was initiated in January 2003 and completed in March  2007 [&lt;ulink linkID="819674" linkType="Reference"&gt;819674&lt;/ulink&gt;]. Data were published in 2010. When a single dose of ambrisentan was administered orally to healthy Japanese subjects under fasted conditions at three dose levels (2.5, 5 and 10 mg), absorption was rapid, and maximum plasma concentrations were reached in 2 to 2.5 h. Ambrisentan exposure increased in an approximately linear fashion with dose. Food intake reduced Cmax by approximately 17%. The fraction of parent drug excreted into the urine up to 96 and 120 h after dosing was less than 4.0% at the three dose levels. The drug was safe and well tolerated [&lt;ulink linkID="1207275" linkType="Reference"&gt;1207275&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2000, BASF had completed phase I trials [&lt;ulink linkID="394232" linkType="Reference"&gt;394232&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Idiopathic pulmonary fibrosis&lt;/subtitle&gt;In December 2008, Gilead began a global phase III trial (&lt;ulink linkID="30302" linkType="Protocol"&gt;NCT00768300&lt;/ulink&gt;, GS-US-231-0101, ARTEMIS-IPF) of the drug for idiopathic pulmonary fibrosis. The randomized, double-blind placebo-controlled, parallel group, safety and efficacy study was to recruit patients (n = 600) diagnosed with IPF in the past 3 years. The primary endpoint was time-to-death or disease progression. The trial was scheduled for completion in December 2012 [&lt;ulink linkID="979561" linkType="Reference"&gt;979561&lt;/ulink&gt;], [&lt;ulink linkID="979522" linkType="Reference"&gt;979522&lt;/ulink&gt;]; in July 2010, enrollment was ongoing with more than 50% of the patients already enrolled [&lt;ulink linkID="1117503" linkType="Reference"&gt;1117503&lt;/ulink&gt;]. However, in December 2010, the trial was terminated after an interim analysis revealed no evidence of treatment benefit in patients who received ambrisentan [&lt;ulink linkID="1157638" linkType="Reference"&gt;1157638&lt;/ulink&gt;]. In May 2012, data were published showing that the drug had been associated with higher disease progression and death rates in the discontinued IPF trial  [&lt;ulink linkID="1308376" linkType="Reference"&gt;1308376&lt;/ulink&gt;]; in July 2012, similar information was  reported by GSK and Health Canada  [&lt;ulink linkID="1308146" linkType="Reference"&gt;1308146&lt;/ulink&gt;]. In May 2013, similar data from a total of 492 patients were published [&lt;ulink linkID="1417206" linkType="Reference"&gt;1417206&lt;/ulink&gt;], [&lt;ulink linkID="1417454" linkType="Reference"&gt;1417454&lt;/ulink&gt;]. In March 2015, ambrisentan was no longer listed on the company pipeline as being under development for IPF.&lt;/para&gt;&lt;para&gt;In July 2009, a phase III, randomized, double-blind, placebo-controlled, multicenter, parallel-assignment, safety and efficacy study (&lt;ulink linkID="51411" linkType="Protocol"&gt;NCT00879229&lt;/ulink&gt;, GS-US-300-0128, ARTEMIS-PH) began in the US in patients (n = 225) with pulmonary hypertension associated with IPF. The primary endpoint was change from baseline in 6-min walk distance.  The study was due to complete in February 2012. The study was terminated in January 2011 [&lt;ulink linkID="1056844" linkType="Reference"&gt;1056844&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Chronic renal failure&lt;/subtitle&gt;In January 2003, the company was evaluating an appropriate strategy for the development of the compound for the treatment of chronic renal failure [&lt;ulink linkID="475480" linkType="Reference"&gt;475480&lt;/ulink&gt;], [&lt;ulink linkID="476001" linkType="Reference"&gt;476001&lt;/ulink&gt;]. No development has since been reported.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Scleroderma&lt;/subtitle&gt;In March 2010, an open label, single group assignment, clinical study (&lt;ulink linkID="65185" linkType="Protocol"&gt;NCT01093885&lt;/ulink&gt;; Ambrj55501) was initiated in the US, in patients (expected n = 15) with scleroderma, to assess the safety and efficacy of ambrisentan. At that time, the trial was expected to complete in December 2015. In March 2015, the trial was still recruiting patients [&lt;ulink linkID="1649692" linkType="Reference"&gt;1649692&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In May 2015, preclinical data were presented at the 2015 ATS International Conference in Denver, CO.  In young female rats administered with monocrotaline (45 mg/kg) 7 days after left pneumonectomy and allowed to develop pulmonary hypertension over the next 10 days,  tadalafil (7 mg/kg/day) + ambrisentan prevented progressive increase in right ventricular systolic pressure  when compared with the late control group at the end of treatment period [&lt;ulink linkID="1679497" linkType="Reference"&gt;1679497&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2014, preclinical data were presented at the 2014 ATS International Conference in San Diego, CA. In male Sprague Dawley rats, ambrisentan and &lt;ulink linkID="54614" linkType="Drug"&gt;riociguat&lt;/ulink&gt; showed concentration-dependent effects on endothelin-1-induced contraction of rat pulmonary arteries while synergistic activity was observed when both were given in combination [&lt;ulink linkID="1557779" linkType="Reference"&gt;1557779&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2003, preclinical data were presented at the 33rd Neuroscience meeting in New Orleans, LA. The effect of ambrisentan was tested on cerebral microcirculation after global ischemia in gerbils. Treatment consisted of 8 min of reperfusion of either normal saline (NS) or ambrisentan (5 mg/kg and 30 mg/kg iv) after 15 min of bilateral carotid artery occlusion. Leukocyte-endothelium-interactions, assessed by intravital fluorescent microscopy of postcapillary subsurface venules, were dose-dependently reduced after injection of ambrisentan. Selective inhibition of endogenous endothelin-1, using ambrisentan during reperfusion, reduced postischemic inflammatory reactions and possibly accounted for the reduced neuronal cell death after stroke [&lt;ulink linkID="513251" linkType="Reference"&gt;513251&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2002, Myogen published preclinical results from an ambrisentan study in stent-induced restenosis, which demonstrated that ambrisentan, administered orally, significantly reduced the narrowing of the coronary arteries of pigs following angioplasty and coronary stent implantation [&lt;ulink linkID="443383" linkType="Reference"&gt;443383&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt; Ambrisentan is a member of a series of endogenous endothelin A antagonists that are derivatives of 3,3-diarylpropionic acid and structural follow ups of LU-135272  [&lt;ulink linkID="343902" linkType="Reference"&gt;343902&lt;/ulink&gt;]. It is a selective antagonist, with an ETA/ETB ratio of 250 [&lt;ulink linkID="453487" linkType="Reference"&gt;453487&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In September 2009, the EMEA's Pediatric Committee (PDCO) adopted a positive opinion on a pediatric investigation plan (PIP) for the drug in the area of cardiovascular diseases [&lt;ulink linkID="1045656" linkType="Reference"&gt;1045656&lt;/ulink&gt;]. In February 2013, the PDCO adopted a positive opinion on modifications to the  PIP [&lt;ulink linkID="1384167" linkType="Reference"&gt;1384167&lt;/ulink&gt;]. In September 2014, the PDCO adopted a positive opinion on modification to the agreed PIP for PAH [&lt;ulink linkID="1595843" linkType="Reference"&gt;1595843&lt;/ulink&gt;].  In October 2016,   the EMA's Pediatric Committee adopted a positive opinion on further modification to an agreed  PIP for the treatment of  pulmonary arterial hypertension  [&lt;ulink linkID="1870943" linkType="Reference"&gt;1870943&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2007, following the drug's US approval, the treatment was to be available through Gilead's Letairis Education and Access Program, due to the drug's risk of inducing liver injury and birth defects. At that time, the company launched Gilead Solutions, a program designed to help patients navigate the ambrisentan reimbursement process and minimize barriers to the treatment [&lt;ulink linkID="805359" linkType="Reference"&gt;805359&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;George E Billman, Department of Physiology and Cell Biology, &lt;ulink linkType="Company" linkID="20649"&gt;Ohio State University&lt;/ulink&gt;, 304 Hamilton Hall, 1645 Neil Avenue, Columbus OH, USA&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Submission date: 1 July 2002&lt;/subtitle&gt;&lt;subtitle&gt;Publication date: 29 July 2002&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;In 1988, Yanagisawa et al [&lt;ulink linkType="reference" linkID="456847"&gt;456847&lt;/ulink&gt;] identified a potent vascular contracting factor in the culture medium of bovine aortic and pulmonary endothelial cells, that was named endothelin. It has been shown subsequently that endothelin is actually a family of three 21 amino acid peptides, ET-1, ET-2, and ET-3 [&lt;ulink linkType="reference" linkID="456848"&gt;456848&lt;/ulink&gt;], that are potent modulators of vascular tone, cell proliferation and hormone production [&lt;ulink linkType="reference" linkID="274301"&gt;274301&lt;/ulink&gt;]. ET-1 is believed to be the most physiologically important among the three peptides [&lt;ulink linkType="reference" linkID="456848"&gt;456848&lt;/ulink&gt;]. Two distinct G-protein coupled receptor subtypes, ETA and ETB, mediate the actions of these peptides [&lt;ulink linkType="reference" linkID="274301"&gt;274301&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="242579"&gt;242579&lt;/ulink&gt;]. ETA binds ET-1 and ET-2 with a higher affinity than ET-3, while ETB has similar affinities for all three endothelin isoforms [&lt;ulink linkType="reference" linkID="274301"&gt;274301&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="242579"&gt;242579&lt;/ulink&gt;]. Both receptor subtypes are present in various tissues in different proportions. ETA is predominately located on vascular smooth muscle, and when stimulated, provokes vasoconstriction and cell proliferation [&lt;ulink linkType="reference" linkID="274301"&gt;274301&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="242579"&gt;242579&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="441396"&gt;441396&lt;/ulink&gt;]. In contrast, ETs binding to ETB on endothelial cells provoke a NO-mediated vasorelaxation, whereas receptors located on vascular smooth muscle are involved in vasoconstriction [&lt;ulink linkType="reference" linkID="441396"&gt;441396&lt;/ulink&gt;]. ETB also plays an important role in sodium and water resorption from distal tubules in the kidney [&lt;ulink linkType="reference" linkID="441396"&gt;441396&lt;/ulink&gt;]. The activation of the endothelin system may contribute to the pathological response in several cardiovascular diseases, including chronic renal failure, hypertension (pulmonary and systemic) and heart failure [&lt;ulink linkType="reference" linkID="441396"&gt;441396&lt;/ulink&gt;]. As such, the selective inhibition of endothelin receptors offers considerable promise as a novel therapeutic approach for the management of these often intractable cardiovascular diseases.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="18425"&gt;Ambrisentan&lt;/ulink&gt; (LU-208075, BSF-208075) is a 3,3-diarylpropionic acid derivative [&lt;ulink linkType="reference" linkID="373160"&gt;373160&lt;/ulink&gt;]. It is a second-generation small molecule selective ETA antagonist (ETRA), based upon the lead compound, &lt;ulink linkType="Drug" linkID="15500"&gt;darusentan&lt;/ulink&gt; (LU-135252), from a family of propionic acid derivatives [&lt;ulink linkType="reference" linkID="217058"&gt;217058&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="430163"&gt;430163&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Reaction of a symmetrically substituted benzophenone derivative with methyl chloroacetate first led to a glyceridic ester (epoxide) in good yields. The opening of this epoxide via Lewis acid-catalyzed addition of an alcohol then afforded, in excellent yields, an alpha-hydroxy ester, which subsequently underwent a nucleophilic substitution by a pyrimidine derivative to lead to another intermediate in good yields. Finally, the methyl ester protecting group on this intermediate was hydrolyzed by potassium hydroxide, producing the desired compound [&lt;ulink linkType="reference" linkID="217058"&gt;217058&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="18425"&gt;Ambrisentan&lt;/ulink&gt; is an orally active selective antagonist of ETA. In canine cell lines expressing human ETA and ETB, &lt;ulink linkType="Drug" linkID="18425"&gt;ambrisentan&lt;/ulink&gt; and the related compound, LU-302146 (BSF-302146), have nearly 100-fold selectivity for ETA versus ETB [&lt;ulink linkType="reference" linkID="373160"&gt;373160&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="343902"&gt;343902&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="18425"&gt;Ambrisentan&lt;/ulink&gt; bound to cloned human ETA presents a Ki value of 0.63 nM compared to a Ki value of 48.7 nM at ETB [personal communication, reported in 441495]. Oral administration (10 mg/kg) also inhibited big ET-1-induced increases in arterial blood pressure [&lt;ulink linkType="reference" linkID="373160"&gt;373160&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="343902"&gt;343902&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In mini-pigs models, &lt;ulink linkType="Drug" linkID="18425"&gt;ambrisentan&lt;/ulink&gt; significantly reduced the impairment of the pancreatic mircocirculation that results from the ischemia and reperfusion associated with transplantation [&lt;ulink linkType="reference" linkID="409483"&gt;409483&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="441496"&gt;441496&lt;/ulink&gt;]. Heterotropic pancreas transplantation was performed in mini-pigs, with half the animals receiving &lt;ulink linkType="Drug" linkID="18425"&gt;ambrisentan&lt;/ulink&gt;, and half receiving placebo. Authors reported that &lt;ulink linkType="Drug" linkID="18425"&gt;ambrisentan&lt;/ulink&gt;-treated animals exhibited significantly lower morphological damage, better reperfusion pO2 values, and improved erythrocyte flux transplantation [&lt;ulink linkType="reference" linkID="409483"&gt;409483&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="441496"&gt;441496&lt;/ulink&gt;]. In a similar manner, the effects of oral &lt;ulink linkType="Drug" linkID="18425"&gt;ambrisentan&lt;/ulink&gt; on restenosis associated with coronary artery stents were evaluated in pigs [&lt;ulink linkType="reference" linkID="441495"&gt;441495&lt;/ulink&gt;]. Percutaneous transluminal coronary angioplasty with stent implantation was completed on 37 pigs. Seven animals died as the result of ventricular fibrillation, and were excluded from the study, and the 30 surviving animals were randomly assigned to either &lt;ulink linkType="Drug" linkID="18425"&gt;ambrisentan&lt;/ulink&gt; (10 mg/kg/day) or vehicle-treated groups (treated for 6 weeks after stent implantation). In the treated groups, &lt;ulink linkType="Drug" linkID="18425"&gt;ambrisentan&lt;/ulink&gt; significantly reduced neointimal thickness, resulting in a larger total coronary lumen. The authors concluded that the antiproliferative effects of this selective ETA antagonist would significantly reduce restenosis, which is the primary complication associated with stent-implantation.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;In dogs, &lt;ulink linkType="Drug" linkID="18425"&gt;ambrisentan&lt;/ulink&gt; had a bioavailability in excess of 90% and a long duration of action (&gt; 6 h) following oral administration [&lt;ulink linkType="reference" linkID="373160"&gt;373160&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="343902"&gt;343902&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;No toxicity data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;In December 2000, Myogen signed an agreement with &lt;ulink linkType="Company" linkID="24093"&gt;BASF Pharma&lt;/ulink&gt; (now &lt;ulink linkType="Company" linkID="13601"&gt;Abbott Laboratories&lt;/ulink&gt;) to develop and test &lt;ulink linkType="Drug" linkID="18425"&gt;ambrisentan&lt;/ulink&gt;. In the press release announcing this agreement, it was reported that &lt;ulink linkType="Company" linkID="24093"&gt;BASF Pharma&lt;/ulink&gt; had completed phase I studies [&lt;ulink linkType="reference" linkID="394232"&gt;394232&lt;/ulink&gt;]. By August 2001, Myogen was in the process of initiating phase II investigation for chronic heart failure, kidney failure and pulmonary hypertension [&lt;ulink linkType="reference" linkID="420580"&gt;420580&lt;/ulink&gt;], and in January 2002, the company stated that the drug was 'ready to enter phase II trials' for the treatment of CHF and pulmonary hypertension [&lt;ulink linkType="reference" linkID="437037"&gt;437037&lt;/ulink&gt;]. The results of clinical studies have not, however, been made available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side Effects and Contraindications&lt;/subtitle&gt;No data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;As previously noted, there is accumulating evidence that elevations in endothelin may contribute significantly to the etiology of many cardiovascular diseases. The actions of endothelin are mediated via the activation of G-protein coupled endothelin receptors (ETA and ETB). The selective inhibition of these receptors, therefore, could have important therapeutic potential. Not surprisingly, the identification of potential ETRAs has received considerable attention from the pharmaceutical industry. At present, there remains some debate as to what represents the best therapeutic approach, selective (ETA) or nonselective (ETA and ETB) endothelin receptor antagonism [&lt;ulink linkType="reference" linkID="456856"&gt;456856&lt;/ulink&gt;]. More comprehensive clinical studies will be required before a definitive resolution to this controversy can be achieved.&lt;/para&gt;&lt;para&gt;At present, the limited data available for &lt;ulink linkType="Drug" linkID="18425"&gt;ambrisentan&lt;/ulink&gt; suggest that the antiproliferative effects of this selective ETA receptor antagonist may prove useful in the prevention of restenosis associated with coronary stent implantation. Data also suggest that this drug may reduce the injury to the microcirculation that results from ischemia/reperfusion during organ transplantation. Other potential applications of this drug are the treatment of heart failure and pulmonary hypertension. It must be emphasized that the effects of this drug in patients remain to be determined. Given the important role that endothelin plays in a variety of cardiovascular diseases, however, it seems reasonable that endothelin receptor antagonists will in the not too distant future become important therapeutic agents for the management of many cardiovascular diseases.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2014-02-06T00:00:00.000Z</StatusDate><Source id="1685980" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2010-09-17T00:00:00.000Z</StatusDate><Source id="1133535" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2009-05-01T00:00:00.000Z</StatusDate><Source id="1616181" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2010-04-28T00:00:00.000Z</StatusDate><Source id="1094595" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2012-02-02T00:00:00.000Z</StatusDate><Source id="1259131" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16450">Gilead Sciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2007-06-30T00:00:00.000Z</StatusDate><Source id="805359" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2009-01-13T00:00:00.000Z</StatusDate><Source id="1348853" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2015-06-30T00:00:00.000Z</StatusDate><Source id="1687641" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2008-06-30T00:00:00.000Z</StatusDate><Source id="1338151" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2009-04-02T00:00:00.000Z</StatusDate><Source id="1687648" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2008-08-25T00:00:00.000Z</StatusDate><Source id="1423684" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2008-11-04T00:00:00.000Z</StatusDate><Source id="1412456" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2015-06-30T00:00:00.000Z</StatusDate><Source id="1687641" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2011-11-01T00:00:00.000Z</StatusDate><Source id="1942200" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2015-06-12T00:00:00.000Z</StatusDate><Source id="1687643" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2008-05-22T00:00:00.000Z</StatusDate><Source id="1716965" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><StatusDate>2012-12-31T00:00:00.000Z</StatusDate><Source id="1354217" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16450">Gilead Sciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><StatusDate>2010-12-09T00:00:00.000Z</StatusDate><Source id="1157638" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3512">Lung disease pulmonary hypertension</Indication><StatusDate>2010-11-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3513">Chronic thromboembolic pulmonary hypertension</Indication><StatusDate>2015-04-07T00:00:00.000Z</StatusDate><Source id="1648412" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16450">Gilead Sciences Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="55">Cardiac failure</Indication><StatusDate>2006-09-12T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16450">Gilead Sciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3512">Lung disease pulmonary hypertension</Indication><StatusDate>2010-11-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16450">Gilead Sciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1867">Pulmonary hypertension</Indication><StatusDate>2012-09-27T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3512">Lung disease pulmonary hypertension</Indication><StatusDate>2010-11-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16450">Gilead Sciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1105">Scleroderma</Indication><StatusDate>2018-04-10T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="DE">Germany</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="69">Renal failure</Indication><StatusDate>2001-11-29T00:00:00.000Z</StatusDate><Source id="431411" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="DE">Germany</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="55">Cardiac failure</Indication><StatusDate>2001-11-29T00:00:00.000Z</StatusDate><Source id="431411" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="69">Renal failure</Indication><StatusDate>2001-03-22T00:00:00.000Z</StatusDate><Source id="398274" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2010-10-19T00:00:00.000Z</StatusDate><Source id="1259130" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14356">BASF SE</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="69">Renal failure</Indication><StatusDate>2000-12-19T00:00:00.000Z</StatusDate><Source id="394232" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14356">BASF SE</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="69">Renal failure</Indication><StatusDate>1998-07-28T11:36:47.000Z</StatusDate><Source id="291736" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3513">Chronic thromboembolic pulmonary hypertension</Indication><StatusDate>2012-09-19T00:00:00.000Z</StatusDate><Source id="1324911" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2012-08-15T00:00:00.000Z</StatusDate><Source id="1685979" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2006-03-06T00:00:00.000Z</StatusDate><Source id="654111" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2006-03-06T00:00:00.000Z</StatusDate><Source id="654111" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2006-03-06T00:00:00.000Z</StatusDate><Source id="654111" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2009-05-04T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2009-04-20T00:00:00.000Z</StatusDate><Source id="1747964" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16450">Gilead Sciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="1105">Scleroderma</Indication><StatusDate>2010-03-25T00:00:00.000Z</StatusDate><Source id="1649692" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2009-04-02T00:00:00.000Z</StatusDate><Source id="1687648" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2015-06-30T00:00:00.000Z</StatusDate><Source id="1687641" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2015-06-12T00:00:00.000Z</StatusDate><Source id="1687643" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2015-06-30T00:00:00.000Z</StatusDate><Source id="1687641" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3512">Lung disease pulmonary hypertension</Indication><StatusDate>2006-08-31T00:00:00.000Z</StatusDate><Source id="689058" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16450">Gilead Sciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3512">Lung disease pulmonary hypertension</Indication><StatusDate>2006-08-31T00:00:00.000Z</StatusDate><Source id="689058" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3512">Lung disease pulmonary hypertension</Indication><StatusDate>2006-08-31T00:00:00.000Z</StatusDate><Source id="689058" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16956">Gilead Colorado Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2003-01-06T00:00:00.000Z</StatusDate><Source id="475480" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16956">Gilead Colorado Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2004-01-08T00:00:00.000Z</StatusDate><Source id="518605" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16956">Gilead Colorado Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2004-01-08T00:00:00.000Z</StatusDate><Source id="518605" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16956">Gilead Colorado Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2004-01-08T00:00:00.000Z</StatusDate><Source id="518605" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16956">Gilead Colorado Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2004-01-08T00:00:00.000Z</StatusDate><Source id="518605" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16956">Gilead Colorado Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="69">Renal failure</Indication><StatusDate>2000-12-19T00:00:00.000Z</StatusDate><Source id="394232" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16956">Gilead Colorado Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2005-02-02T00:00:00.000Z</StatusDate><Source id="582980" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16956">Gilead Colorado Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2005-02-02T00:00:00.000Z</StatusDate><Source id="582980" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16450">Gilead Sciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2006-11-17T00:00:00.000Z</StatusDate><Source id="743927" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2006-03-06T00:00:00.000Z</StatusDate><Source id="654111" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16450">Gilead Sciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2006-12-18T00:00:00.000Z</StatusDate><Source id="752283" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2001-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2003-01-31T00:00:00.000Z</StatusDate><Source id="819674" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16450">Gilead Sciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2007-06-15T00:00:00.000Z</StatusDate><Source id="805359" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2008-04-25T00:00:00.000Z</StatusDate><Source id="900080" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2007-10-31T00:00:00.000Z</StatusDate><Source id="846814" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2010-07-23T00:00:00.000Z</StatusDate><Source id="1128603" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16450">Gilead Sciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><StatusDate>2008-12-31T00:00:00.000Z</StatusDate><Source id="979561" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16450">Gilead Sciences Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="55">Cardiac failure</Indication><StatusDate>2001-11-29T00:00:00.000Z</StatusDate><Source id="431411" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="16450">Gilead Sciences Inc</OwnerCompany><Country id="US">US</Country><Indication id="3510">Pulmonary artery hypertension</Indication><AwardedIndication>For Pulmonary arterial hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2006-03-09T00:00:00.000Z</MileStoneDate><Source id="654806" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="28355">GlaxoSmithKline plc</OwnerCompany><Country id="JP">Japan</Country><Indication id="1867">Pulmonary hypertension</Indication><AwardedIndication>Chronic thromboembolic pulmonary hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-06-17T00:00:00.000Z</MileStoneDate><Source id="1443760" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16450">Gilead Sciences Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><AwardedIndication>Treatment idiopathic pulmonary fibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="9">Withdrawn</DesignationApplicationStatus><MileStoneDate>2011-06-01T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16450">Gilead Sciences Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><AwardedIndication>Treatment idiopathic pulmonary fibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2010-10-01T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16450">Gilead Sciences Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><AwardedIndication>Treatment idiopathic pulmonary fibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2010-07-08T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16450">Gilead Sciences Inc</OwnerCompany><Country id="US">US</Country><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><AwardedIndication>Treatment of idiopathic pulmonary fibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2009-12-23T00:00:00.000Z</MileStoneDate><Source id="1276550" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="28355">GlaxoSmithKline plc</OwnerCompany><Country id="TW">Taiwan</Country><Indication id="3510">Pulmonary artery hypertension</Indication><AwardedIndication>Treatment of primary pulmonary arterial hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2009-05-04T00:00:00.000Z</MileStoneDate><Source id="1685979" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16450">Gilead Sciences Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3510">Pulmonary artery hypertension</Indication><AwardedIndication>Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="6">Maintenance Recommendation</DesignationApplicationStatus><MileStoneDate>2008-07-29T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="28355">GlaxoSmithKline plc</OwnerCompany><Country id="AU">Australia</Country><Indication id="3510">Pulmonary artery hypertension</Indication><AwardedIndication>For the treatment of patients with pulmonary arterial hypertension (PAH) to improve exercise capacity, delay clinical worsening and decrease the symptoms of PAH.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2007-07-05T00:00:00.000Z</MileStoneDate><Source id="1620464" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16450">Gilead Sciences Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3510">Pulmonary artery hypertension</Indication><AwardedIndication>Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate>2006-09-01T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16450">Gilead Sciences Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3510">Pulmonary artery hypertension</Indication><AwardedIndication>Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate>2005-08-01T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16450">Gilead Sciences Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3510">Pulmonary artery hypertension</Indication><AwardedIndication>Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2005-04-11T00:00:00.000Z</MileStoneDate><Source id="1716113" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16450">Gilead Sciences Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3510">Pulmonary artery hypertension</Indication><AwardedIndication>Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2005-03-03T00:00:00.000Z</MileStoneDate><Source id="1706152" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16956">Gilead Colorado Inc</OwnerCompany><Country id="US">US</Country><Indication id="3510">Pulmonary artery hypertension</Indication><AwardedIndication>Treatment of pulmonary arterial hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2004-07-16T00:00:00.000Z</MileStoneDate><Source id="552210" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00659"><Name>Endothelin ET-A receptor</Name><SwissprotNumbers><Swissprot>P21450</Swissprot><Swissprot>P25101</Swissprot><Swissprot>P26684</Swissprot><Swissprot>Q29010</Swissprot><Swissprot>Q5KSU9</Swissprot><Swissprot>Q61614</Swissprot><Swissprot>Q95L55</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2157455" linkType="reference" linkID="2157455"&gt;2157455&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="13601">Abbott Laboratories</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="16450">Gilead Sciences Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="28355">GlaxoSmithKline plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>Cc1cc(nc(n1)O[C@H](C(=O)O)C(c2ccccc2)(c3ccccc3)OC)C</Smiles></StructureSmiles><Deals><Deal id="108701" title="GSK to commercialize Myogen's ambrisentan for PAH outside the US    "/><Deal id="114431" title="BASF Pharma and Myogen to co-develop ambrisentan"/></Deals><PatentFamilies><PatentFamily id="1130636" number="WO-09526716" title="Pyrimidine or triazine carboxylic acid derivatives to be used as medicaments."/><PatentFamily id="1165532" number="WO-09425442" title="3-(Hetero)aryl carboxylic acid derivatives, methods of preparing them and intermediates used in their preparation"/><PatentFamily id="1171056" number="WO-2008073928" title="Composition for treating a pulmonary hypertension"/><PatentFamily id="1407432" number="WO-2011004402" title="Improved process for the preparation of ambrisentan and novel intermediates thereof"/><PatentFamily id="1408611" number="WO-2012051559" title="Compositions and methods of treating pulmonary hypertension"/><PatentFamily id="1475782" number="WO-2008097468" title="Selective endothelin type-A antagonists"/><PatentFamily id="1849916" number="WO-2010017917" title="Pharmaceutical formulation for lowering pulmonary blood pressure"/><PatentFamily id="1955680" number="WO-2005077347" title="Use of endothelin antagonists to prevent restenosis"/><PatentFamily id="2047755" number="WO-2010091877" title="Process for producing ambrisentan"/><PatentFamily id="2056538" number="CN-102219748" title="Amorphous ambrisentan and preparation method thereof"/><PatentFamily id="2068290" number="WO-2008009071" title="Combination therapy using betaine and endothelin antagonists"/><PatentFamily id="2126538" number="WO-2012058993" title="Use of ambrisentan for preventing or alleviating cardiac function injury caused by hypoxia"/><PatentFamily id="2182443" number="WO-2009017777" title="Metabolites and derivatives of ambrisentan"/><PatentFamily id="2429930" number="WO-2012167406" title="Method for preparing optically pure (+)-ambrisentan and (+)-darusentan"/><PatentFamily id="2464405" number="CN-102887861" title="A kind of ambrisentan raw planar new crystal form and preparation method thereof"/><PatentFamily id="2507762" number="CN-103012280" title="Method for preparing ambrisentan"/><PatentFamily id="2517258" number="WO-2013057468" title="Process for the preparation of an endothelin receptor antagonist"/><PatentFamily id="2543395" number="WO-2011114338" title="A Process for the preparation of highly pure ambrisentan"/><PatentFamily id="2581958" number="WO-2013130119" title="Method for treating a pulmonary hypertension condition without companion diagnosis"/><PatentFamily id="2636304" number="WO-2013170778" title="Intermediate compound for preparing ambrisentan, preparing method thereof, and preparing method of ambrisentan"/><PatentFamily id="2641589" number="WO-09611914" title="New carboxylic acid derivatives, their preparation and their use"/><PatentFamily id="2660187" number="WO-2014003678" title="Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil"/><PatentFamily id="2660419" number="WO-2014001511" title="Preparation process of carboxylic acid derivatives and intermediates thereof"/><PatentFamily id="2672688" number="CN-103396370" title="A ambrisentan purification method"/><PatentFamily id="2703963" number="CN-103524425" title="Crystal form V of ambrisentan as well as preparation method and application thereof"/><PatentFamily id="2703964" number="CN-103524424" title="Crystal form VI of ambrisentan as well as preparation method and application thereof"/><PatentFamily id="2731431" number="CN-103739557" title="Synthetic method of 4,6-dimethyl-2-methyl sulfonyl pyridine"/><PatentFamily id="2746710" number="CN-103709106" title="Stereoselectivity preparation method for Letairis"/><PatentFamily id="2761307" number="CN-103860525" title="A capsule type inhalation powder a containing active component of ambrisentane and its preparation technology"/><PatentFamily id="2765193" number="CN-103772292" title="Ambrisentan-DMSO co-crystal, preparation method and application thereof"/><PatentFamily id="2798048" number="WO-2014139087" title="Racemization method of chiral 2-[(4,6-dimethylpyrimidine-2-yl)oxy]-3-methoxy-3,3-diphenyl propionic acid"/><PatentFamily id="2798966" number="WO-2014139086" title="Method for preparing ambrisentan"/><PatentFamily id="2816956" number="CN-103919747" title="Ambrisentan tablet composition and preparation method thereof  "/><PatentFamily id="2841190" number="CN-104177300" title="An ambrisentan degradation product and the preparation method thereof"/><PatentFamily id="2878253" number="CN-104280480" title="A method for separating and detecting anryu method for etimicin and its related substance"/><PatentFamily id="2879421" number="CN-104237432" title="Method using high-efficient liquid phase chromatography method analyzing ambrisentan and its preparation and content"/><PatentFamily id="2879430" number="CN-104237399" title="Method for preparation of vinorelbine"/><PatentFamily id="2905985" number="CN-104359993" title="Detection method of substance related to ambrisentan"/><PatentFamily id="2913348" number="WO-2015046404" title="Therapeutic agent or prophylactic agent for pulmonary hypertension"/><PatentFamily id="2917563" number="CN-104382840" title="S-vinorelbine oral administration composition and preparation method"/><PatentFamily id="2936921" number="CN-104515816" title="One of vinorelbine raw material and related material preparation and detecting method"/><PatentFamily id="2944937" number="CN-104592129" title="An improved preparation method of ambrisentan"/><PatentFamily id="296184" number="WO-2010017918" title="Amorphous ambrisentan"/><PatentFamily id="3013345" number="CN-104844524" title="Synthesis method of ambrisentan"/><PatentFamily id="3197986" number="CN-105581990" title="Ambrisentan tablet and its preparation method"/><PatentFamily id="320486" number="WO-00026170" title="Method For Racemate Splitting Of 2-Hydroxypropionic Acids"/><PatentFamily id="3267668" number="CN-105801404" title="A s-2-hydroxy - -3 - methoxy - -3, 3-diphenyl-propionic acid and preparation method thereof"/><PatentFamily id="332098" number="WO-2008073927" title="Ambrisentan combined with a renin inhibitor for hypertensive disorder"/><PatentFamily id="3416829" number="WO-2016168403" title="Pulmonary embolism apparatus"/><PatentFamily id="3431854" number="CN-106011194" title="Preparation method of ambrisentan"/><PatentFamily id="3468914" number="CN-106146405" title="Drug intermediate and preparing method and application thereof"/><PatentFamily id="375040" number="WO-2012017441" title="Improved process to prepare S-2-hydroxy-3-methoxy-3,3-diphenyl propionic acid"/><PatentFamily id="3989006" number="WO-2018053406" title="Methods and systems for screening candidate compounds for their potential to cause systemic or hepatic toxicity"/><PatentFamily id="4040489" number="WO-2018081567" title="Combination therapy for treating pulmonary hypertension"/><PatentFamily id="4131183" number="CN-108250151" title="Preparation method of ambrisentan"/><PatentFamily id="4344770" number="WO-2019010445" title="Compositions and method for treating pulmonary hypertension"/><PatentFamily id="4395641" number="CN-109276546" title="Ambrisentan tablet composition"/><PatentFamily id="4400152" number="CN-109320464" title="Small particle size ambrisentan purification method"/><PatentFamily id="4400153" number="CN-109320463" title="Small particle size ambrisentan purification method"/><PatentFamily id="4509785" number="CN-109705042" title="A ambrisentan preparation method"/><PatentFamily id="519324" number="WO-2010070658" title="Improved process for the preparation of endothelin receptor antagonists"/><PatentFamily id="628578" number="US-20090069353" title="Deuterium-enriched ambrisentan"/><PatentFamily id="677101" number="CN-102584716" title="Crystal form and preparation method of vinorelbine"/><PatentFamily id="894736" number="EP-02476670" title="Stable solid salts of ambrisentan"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="1">Analyte</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>15</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>7</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>12</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="14">Tentative</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>7</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="4">Delivery device</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>19</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>4</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Qualyst Transporter Solutions LLC" id="1009689"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CoNCERT Pharmaceuticals Inc" id="1021896"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="MSN Laboratories Ltd" id="1025511"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Huahai Pharmaceutical Group Co Ltd" id="1030330"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tianjin Institute of Pharmaceutical Research" id="1031863"/><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kern Pharma SL" id="1036658"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Protia LLC" id="1043660"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tianjin Kanghong Pharmaceutical Technology Development Co Ltd" id="1044071"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Xspray Microparticles Ab" id="1047942"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tianjin Chase Sun Pharmaceutical Co Ltd" id="1051535"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tianjian Pharmaceuticals Group" id="1053972"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanford Health" id="1054380"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="China National Pharmaceutical Group Corporation" id="1055632"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tianjin KingYork Group" id="1056725"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pulmokine Inc" id="1057124"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ningbo Renjian Pharmaceutical Co Ltd" id="1059922"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai MeiYue Biotech Development Co Ltd" id="1068494"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wuhan QiRui Pharmaceuticals Co Ltd" id="1068498"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AbbVie Inc" id="1072507"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sino Biopharmaceutical Ltd" id="1073089"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Humanwell Healthcare (Group) Co Ltd" id="1074338"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Jialin Pharmaceutical Co Ltd" id="1074406"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wuhan Biocause Pharmaceutical Development Co Ltd" id="1077489"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Allergan plc" id="1088700"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>3</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Yellow River Delta Jingbo Chemical Research Institute Co Ltd" id="1094335"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shijiazhuang Boce Biotechnology Co Ltd" id="1103557"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nanjing Zeheng Medical Technology Development Co Ltd" id="1109001"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Advent International" id="1123769"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Liaoning Nuokang Biopharma Co Ltd" id="1130167"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Weihai Guanbiao Information Technology Co Ltd" id="1146006"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Abbott Laboratories" id="13601"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chinese Academy of Medical Military Sciences" id="14168"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BASF SE" id="14356"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>3</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cipla Ltd" id="15503"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gilead Sciences Inc" id="16450"/><CountAsOwner>7</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Toray Industries Inc" id="20406"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Rochester" id="20669"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chinese Academy of Sciences" id="23863"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Colorado System" id="25520"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Edwards Lifesciences Corp" id="27686"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GlaxoSmithKline plc" id="28355"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Natco Pharma Ltd" id="28692"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zydus-Cadila Group" id="29062"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangsu Kanion Pharmaceutical Co Ltd" id="30980"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Royalty Pharma" id="DOL1000090"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johannes Gutenberg Universitat Mainz" id="DOL1000148"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></Drug></drugRecordsOutput>